Tag: SUM-101
-
New Tanzanian Malaria Vaccine SUM-101 Shows Strong Immune Response in Early Trials
Promising early results for SUM-101 in Tanzanian adults A new experimental malaria vaccine, SUM-101, has generated encouraging immune responses in its first human trial conducted with Tanzanian adults who have prior exposure to malaria. The study, conducted in Dar es Salaam and led by researchers including Aina-ekisha Kahatano and Maxmillian Mpina, aims to assess safety,…
-
SUM-101 Malaria Vaccine Shows Strong Immune Response
Overview of the SUM-101 Trial A new experimental malaria vaccine known as SUM-101 has generated hopeful results in its initial testing phase. Conducted among Tanzanian adults who have lived with malaria exposure, the early trial aimed to assess the vaccine’s safety and its ability to stimulate the immune system — a key step before larger…